The CTA1-DD vaccine adjuvant binds to human B cells and potentiates their T cell stimulating ability

Vaccine

Volumn 22, Issue 2, 2003, Pages 185-193

  Eriksson, A ^a   Lycke, N ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Cholera toxin; Human B cells; Immunomodulation; Targeted adjuvants

Indexed keywords

CHEMOKINE; CHOLERA TOXIN; CTA1 DD VACCINE ADJUVANT; CYTOKINE; HYBRID PROTEIN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 6; INTERLEUKIN 8; IONOMYCIN; PHORBOL 13 ACETATE 12 MYRISTATE; POKEWEED MITOGEN; STAPHYLOCOCCUS PROTEIN A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; CELL FUNCTION; CELL PROLIFERATION; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOMODULATION; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0242575934     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00567-X     Document Type: Article

References (48)

1. Mark A., Bjorksten B., Granstrom M. Immunoglobulin E responses to diphtheria and tetanus toxoids after booster with aluminium-adsorbed and fluid DT-vaccines. Vaccine. 13(7):1995;669-673.
2. Odelram H., Granstrom M., Hedenskog S., Duchen K., Bjorksten B. Immunoglobulin E and G responses to pertussis toxin after booster immunization in relation to atopy, local reactions and aluminium content of the vaccines. Pediatr. Allerg. Immunol. 5(2):1994;118-123.
3. Cox J.C., Coulter A.R. Adjuvants - a classification and review of their modes of action. Vaccine. 15(3):1997;248-256.
4. Gupta R.K. Aluminum compounds as vaccine adjuvants. Adv. Drug Deliv. Rev. 32(3):1998;155-172.
5. Vogel F.R., Powell M.F. A compendium of vaccine adjuvants and excipients. Pharm. Biotechnol. 6:1995;141-228.
6. Medina E., Guzman C.A. Modulation of immune responses following antigen administration by mucosal route. FEMS Immunol. Med. Microbiol. 27(4):2000;305-311.
7. Krieg A.M., Davis H.L. Enhancing vaccines with immune stimulatory CpG DNA. Curr. Opin. Mol. Ther. 3(1):2001;15-24.
8. Elson CO, Dertzbaugh MT. Mucosal adjuvants. In: Ogra PL, Mestecky J, Lamm ME, Strober W, McGhee JR, Bienenstock J, editors. Handbook of mucosal immunology. San Diego, CA, USA: Academic Press; 1999. p. 817-38.
9. Simmons C.P., Ghaem-Magami M., Petrovska L.et al. Immunomodulation using bacterial enterotoxins. Scand. J. Immunol. 53(3):2001;218-226.
10. Levine M.M., Dougan G. Optimism over vaccines administered via mucosal surfaces. Lancet. 351(9113):1998;1375-1376.
11. Spangler B.D. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 56(4):1992;622-647.
12. Rappuoli R., Pizza M., Douce G., Dougan G. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol. Today. 20(11):1999;493-500.
13. Merritt E.A., Hol W.G. AB5 toxins. Curr. Opin. Struct. Biol. 5(2):1995;165-171.
14. Burnette W.N. AB5 ADP-ribosylating toxins: comparative anatomy and physiology. Structure. 2(3):1994;151-158.
15. Levine M.M., Black R.E., Clements M.L.et al. Evaluation in humans of attenuated Vibrio cholerae El Tor Ogawa strain Texas Star-SR as a live oral vaccine. Infect. Immun. 43(2):1984;515-522.
16. van Ginkel F.W., Jackson R.J., Yuki Y., McGhee J.R. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J. Immunol. 165(9):2000;4778-4782.
17. Gluck U., Gebbers J.O., Gluck R. Phase 1 evaluation of intranasal virosomal influenza vaccine with and without E. coli heat-labile toxin in adult volunteers. J. Virol. 73(9):1999;7780-7786.
18. Gluck R., Mischler R., Durrer P. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing E. coli heat-labile toxin as a mucosal adjuvant. J. Infect. Dis. 181(3):2000;1129-1132.
19. Ljungberg U.K., Jansson B., Niss U., Nilsson R., Sandberg B.E., Nilsson B. The interaction between different domains of staphylococcal protein A and human polyclonal IgG, IgA, IgM and F(ab′)2: separation of affinity from specificity. Mol. Immunol. 30(14):1993;1279-1285.
20. Uhlen M., Guss B., Nilsson B., Gatenbeck S., Philipson L., Lindberg M. Complete sequence of the staphylococcal gene encoding protein A. A gene evolved through multiple duplications. J. Biol. Chem. 259(3):1984;1695-1702.
21. Agren L.C., Ekman L., Lowenadler B., Lycke N.Y. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J. Immunol. 158(8):1997;3936-3946.
22. Agren L.C., Ekman L., Lowenadler B., Nedrud J.G., Lycke N.Y. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity. J. Immunol. 162(4):1999;2432-2440.
23. Agren L., Sverremark E., Ekman L.et al. The ADP-ribosylating CTA1-DD-adjuvant enhances T cell-dependent and independent responses by direct action on B cells involving anti-apoptotic Bcl-2- and germinal center-promoting effects. J. Immunol. 164(12):2000;6276-6286.
24. Lycke N. The B-cell targeted CTA1-DD vaccine adjuvant is highly effective at enhancing antibody as well as CTL responses. Curr. Opin. Mol. Ther. 3(1):2001;37-44.
25. Lycke N. The mechanism of cholera toxin adjuvanticity. Res. Immunol. 148(8-9):1997;504-520.
26. Nilsson B., Moks T., Jansson B.et al. A synthetic IgG-binding domain based on staphylococcal protein A. Protein Eng. 1(2):1987;107-113.
27. Srivastava M.D., Srivastava R., Srivastava B.I. Constitutive production of interleukin-8 (IL-8) by normal and malignant human B-cells and other cell types. Leuk. Res. 17(12):1993;1063-1069.
28. Linton P.J., Harbertson J., Bradley L.M. A critical role for B cells in the development of memory CD4 cells. J. Immunol. 165(10):2000;5558-5565.
29. Rivera A., Chen C.C., Ron N., Dougherty J.P., Ron Y. Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations. Int. Immunol. 13(12):2001;1583-1593.
30. Morris S.C., Lees A., Finkelman F.D. In vivo activation of naive T cells by antigen-presenting B cells. J. Immunol. 152(8):1994;3777-3785.
31. Evans D.E., Munks M.W., Purkerson J.M., Parker D.C. Resting B lymphocytes as APC for naive T lymphocytes: dependence on CD40 ligand/CD40. J. Immunol. 164(2):2000;688-697.
32. Shirota H., Sano K., Hirasawa N.et al. B cells capturing antigen conjugated with CpG oligodeoxynucleotides induce Th1 cells by elaborating IL-12. J. Immunol. 169(2):2002;787-794.
33. + T cell activation and CTL effector function. J. Immunol. 168(8):2002;3786-3792.
34. + T cells in CD2-mediated activation. J. Exp. Med. 172(5):1990;1419-1424.
35. Leal I.S., Smedegard B., Andersen P., Appelberg R. Interleukin-6 and interleukin-12 participate in induction of a type 1 protective T-cell response during vaccination with a tuberculosis subunit vaccine. Infect. Immun. 67(11):1999;5747-5754.
36. + T cells. J. Exp. Med. 185(3):1997;461-469.
37. Rieckmann P., Tuscano J.M., Kehrl J.H. Tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in B-lymphocyte function. Methods. 11(1):1997;128-132.
38. Tosato G., Miller J., Marti G., Pike S.E. Accessory function of interleukin-1 and interleukin-6: preferential costimulation of T4 positive lymphocytes. Blood. 75(4):1990;922-930.
39. Bromander A.K., Kjerrulf M., Holmgren J., Lycke N. Cholera toxin enhances alloantigen presentation by cultured intestinal epithelial cells. Scand. J. Immunol. 37(4):1993;452-458.
40. Ranheim E.A., Kipps T.J. Tumor necrosis factor-alpha facilitates induction of CD80 (B7-1) and CD54 on human B cells by activated T cells: complex regulation by IL-4, IL-10, and CD40L. Cell Immunol. 161(2):1995;226-235.
41. Schratzberger P., Dunzendorfer S., Reinisch N., Kahler C.M., Wiedermann C.J. Interleukin-8-induced human peripheral blood B-lymphocyte chemotaxis in vitro. Immunol. Lett. 58(3):1997;167-170.
42. Lycke N., Schon K. The B cell targeted adjuvant, CTA1-DD, exhibits potent mucosal immunoenhancing activity despite pre-existing anti-toxin immunity. Vaccine. 19(17-19):2001;2542-2548.
43. Cong Y., Weaver C.T., Elson C.O. The mucosal adjuvanticity of cholera toxin involves enhancement of costimulatory activity by selective up-regulation of B7.2 expression. J. Immunol. 159(11):1997;5301-5308.
44. Bromander A.K., Kjerrulf M., Holmgren J., Lycke N. Cholera toxin enhances antigen presentation. Adv. Exp. Med. Biol. 6:1995;1501-1506.
45. McGee D.W., Elson C.O., McGhee J.R. Enhancing effect of cholera toxin on interleukin-6 secretion by IEC-6 intestinal epithelial cells: mode of action and augmenting effect of inflammatory cytokines. Infect. Immun. 61(11):1993;4637-4644.
46. Anastassiou E.D., Yamada H., Francis M.L., Mond J.J., Tsokos G.C. Effects of cholera toxin on human B cells. Cholera toxin induces B cell surface DR expression while it inhibits anti-mu antibody-induced cell proliferation. J. Immunol. 145(8):1990;2375-2380.
47. Glueck R. Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization. Vaccine. 20(Suppl. 1):2001;S42-S44.
48. Giudice G.D. Helivax antex biologics. Curr. Opin. Invest. Drugs. 2(7):2001;896-899.